Twist Bioscience Corp: Form 10-Q for the period ended Dec 31, 2024
Filed with the SEC on Feb 3, 2025 and accepted by EDGAR at Feb 3, 2025, 16:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-10-01 to 2024-12-31 | $88.7m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2024-10-01 to 2024-12-31 | $45.9m | us-gaap:CostOfRevenue |
| Research and development | 3 months2024-10-01 to 2024-12-31 | $21.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-10-01 to 2024-12-31 | $56.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-10-01 to 2024-12-31 | −$34.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-10-01 to 2024-12-31 | $24.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-10-01 to 2024-12-31 | $97.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-10-01 to 2024-12-31 | −$31.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-10-01 to 2024-12-31 | −$0.53 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-10-01 to 2024-12-31 | −$0.53 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-10-01 to 2024-12-31 | 59,162,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-10-01 to 2024-12-31 | −$21.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-10-01 to 2024-12-31 | $2.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-12-31 | $221.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $345.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $608.6m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $69.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $152.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-12-31 | $455.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-25-003461. Last ingested by Listed: Nov 3, 2026, 18:01 ET. Listed shows no prices and gives no investment advice.